ANDA 78340, held by Sun Pharm. Imatinib Mesylate.
As of Nov 16, 2026, ANDA 78340 (Imatinib Mesylate), held by Sun Pharm, was first approved by FDA on Dec 3, 2015, with 6 approved supplements and 0 published complete response letters.
Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 3, 2015 | Original application | Approved |
| Imatinib MesylateEQ 100MG BASE · tablet;oral | Imatinib Mesylate | Discontinued |
| Imatinib MesylateEQ 400MG BASE · tablet;oral | Imatinib Mesylate | Discontinued |
| Apr 8, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Supplement 7Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Apr 8, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Dec 3, 2015 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters